Galapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer Drug
By Ben Glickman
Galapagos said it had entered an agreement with Thermo Fisher Scientific to expand manufacturing of its immune-cell cancer treatment candidate.
The company said that Thermo Fisher had agreed to provide CAR-T manufacturing and kitting services for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco area.
Galapagos in November signed a deal with Landmark Bio to manufacture CAR-T in the Boston area.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 04, 2024 16:29 ET (21:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk